Evidence map›Paper›PMID 31566258›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2019

Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Byungji Kim, Ji-Ho Park, Michael J Sailor

Abstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Functional Dendrimer Nanogels for DNA Delivery and Gene Therapy of Tumors.Angewandte Chemie (International ed. in English) · 2025
    Article
  16. Nucleic Acid-Modified Nanoparticles for Cancer Therapeutic Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Byungji KimMaterials Science and Engineering Program, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.ORCID https://orcid.org/0000-0001-8131-5255
Ji-Ho ParkDepartment of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.ORCID https://orcid.org/0000-0002-0721-0428
Michael J SailorMaterials Science and Engineering Program, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.ORCID https://orcid.org/0000-0002-4809-9826

Funding

Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary InfectionsR01AI132413 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael J Sailor · 2017 to 2026
$6.0M
Improving the in Vivo Delivery and Antitumor Efficacy of Antisense DrugsR01CA214550 · NCI · UNIVERSITY OF MINNESOTA · PI PANG, HONGBO · 2017 to 2021
$1.7M
European Union's Horizon 2020 Research and Innovation Staff Exchange (RISE) 778133NCI NIH HHS R01 CA214550NIAID NIH HHS R01 AI132413NIH HHS CBET-1603177NIH HHS R01 AI132413-01NIH HHS R01CA214550-01
6 · The paper itself

Abstract

With the recent FDA approval of the first siRNA-derived therapeutic, RNA interference (RNAi)-mediated gene therapy is undergoing a transition from research to the clinical space. The primary obstacle to realization of RNAi therapy has been the delivery of oligonucleotide payloads. Therefore, the main aims is to identify and describe key design features needed for nanoscale vehicles to achieve effective delivery of siRNA-mediated gene silencing agents in vivo. The problem is broken into three elements: 1) protection of siRNA from degradation and clearance; 2) selective homing to target cell types; and 3) cytoplasmic release of the siRNA payload by escaping or bypassing endocytic uptake. The in vitro and in vivo gene silencing efficiency values that have been reported in publications over the past decade are quantitatively summarized by material type (lipid, polymer, metal, mesoporous silica, and porous silicon), and the overall trends in research publication and in clinical translation are discussed to reflect on the direction of the RNAi therapeutics field.

Indexed as

RNAi TherapeuticsAnimalsDrug CarriersGene EditingHumansNanoparticlesRNA InterferenceRNA, Small InterferingDrug CarriersRNA, Small Interferingdrug deliverygene therapynanoparticlesRNA interferencesiRNA

Identifiers

PMID31566258
PMCPMC6891135

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.